Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07684586 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation Prototypes

StatusWithdrawn
PhasePhase 1
Started2026-07-02
View on ClinicalTrials.gov ↗
Why the trial stopped
The study has been withdrawn given the recent decision to cease further development of camlipixant in refractory chronic cough (RCC) based on Phase 3 program results.
This is an open-label study being conducted in healthy adults, to learn what happens to the study medicine (camlipixant) they are receiving in a person's body over time (a pharmacokinetic \[PK\] study). The goal of the study is to understand how the body processes camlipixant, to check its safety and how well it is tolerated. Participants will receive camlipixant at different dose levels with different formulation types either on an empty stomach or after a meal.

Amendment history 2 changes detected by DataLookout

2026-09-01
critical
Trial status changed: Suspended → Withdrawn
2026-07-25
critical
Trial status changed: Not Yet Recruiting → Suspended
Trial Details
NCT Number NCT07684586
Lead Sponsor GlaxoSmithKline
Conditions Cough
Start Date 2026-07-02
Primary Completion 2027-08-27 (estimated)
Study Completion 2027-08-27 (estimated)
Updated on ClinicalTrials.gov 2026-08-31